Table 7 Two-fold relevancy prediction in terms of WSS@95% on DERP systematic review collections
From: Improving reference prioritisation with PICO recognition
|  | [84] | [119] | [95] | LR | PICO | Δ |
|---|---|---|---|---|---|---|
ACE Inhibitors | 52.3 | 73.3 | *80.1 | 78.5 | 77.6 | -0.9 |
ADHD | 62.2 | 52.6 | *79.3 | 75.5 | 74.5 | -0.9 |
Antihistamines | 14.9 | *23.6 | 13.7 | 4.9 | 5.0 | 0.1 |
Atypical Antipsychotics | 20.6 | 17.0 | *25.1 | 19.9 | 20.9 | 1.0 |
Beta Blockers | 36.7 | 46.5 | 42.8 | *55.5 | 54.1 | -1.4 |
Calcium Channel Blockers | 23.4 | 43.0 | *44.8 | 38.8 | 39.3 | 0.6 |
Estrogens | 37.5 | 41.4 | *47.1 | 41.0 | 43.7 | 2.7 |
NSAIDS | 52.8 | 67.2 | *73.0 | 65.3 | 66.5 | 1.2 |
Opioids | 55.4 | 36.4 | *82.6 | 53.3 | 57.0 | 3.7 |
Oral Hypoglycemic | 8.5 | *13.6 | 11.7 | 7.1 | 8.9 | 1.8 |
Proton Pump Inhibitors | 22.9 | 32.8 | *37.8 | 32.6 | 31.0 | -1.6 |
Skeletal Muscle Relaxants | 26.5 | 37.4 | *55.6 | 40.1 | 45.3 | 5.3 |
Statins | 31.5 | *49.1 | 43.6 | 42.2 | 44.3 | 2.1 |
Triptans | 27.4 | 34.6 | 41.2 | 40.6 | *51.2 | 10.5 |
Urinary Incontinence | 29.6 | 43.2 | *53.0 | 52.4 | 52.4 | 0.0 |
Average | 33.5 | 40.8 | 48.8 | 43.2 | 44.8 | 1.6 |